OPTI
NEUTRALOptiBiotix Director Increases Shareholding
The healthcare company has announced a director has purchased additional shares in the business.
OptiBiotix Health
8.00GBX
3.23%
Market Cap
8.53M
Volume
45.79k
15% of avg
P/E Ratio
NaN
EPS (TTM)
Beta
1.93
Day Range
7.50p - 8.00p
52 Week Range
7.50p8.00p23.50p
8.00p
Upcoming Events
OPTI
NEUTRALOptiBiotix Director Increases Stake
The life sciences company announces its Chief Executive Officer has purchased additional shares in the business.
OPTI
NEUTRALOptiBiotix Health Reports Strong Revenue Growth in Half-Year Results
The life sciences company reported a 102% increase in revenue and improved gross margins, despite ongoing operating losses. Expansion in key markets and new product launches signal potential future growth.
OPTI
NEUTRALOptiBiotix Joins OTCQB Venture Market in the US
The life sciences company has been approved to trade on the OTCQB Venture Market in the US, aiming to increase its visibility and investor base in the country.
OPTI
GOODOptiBiotix Signs Distribution Deal with Major Weight Management Company
The life sciences company has signed a distribution agreement with a major weight management brand to sell its SlimBiome and WellBiome products under the partner's own branding.
OPTI
NEUTRALOptiBiotix Launches SlimBiome in Top US Weight Loss Brand
The life sciences company has launched its appetite-reducing SlimBiome ingredient in a top-selling US weight loss supplement brand.
OPTI
NEUTRALOptiBiotix Health Issues Options to Director
The life sciences company has issued options over new ordinary shares to a director.
OPTI
VERY GOODOptiBiotix Health Reports Strong H1 2025 Results
The life sciences company reports strong growth in revenue, profit, and margins for the first half of 2025, driven by expansion into new markets and cost reductions.
OPTI
NEUTRALOptiBiotix Health PLC Appoints New Broker
The life sciences company has appointed Cairn Financial Advisers LLP as its new broker.
OPTI
BADOptiBiotix Health Reports 35% Revenue Growth Amid Widening Losses in 2024 Results
The life sciences company reported a 35% revenue increase but faced widening losses and margin pressure. Despite growth in key markets, economic uncertainties and supply chain challenges pose risks to future performance.